Shots:

• Cytokinetics to receive $50M in up front & near-term milestone, $20M from RTW for sale of common stock at a price/share of $39.125, ~$330M upon achievement of a commercial milestone along with royalties on sales of omecamtiv mecarbil in the greater China
• Ji Xing will lead the development & commercialization of the product in its territory at its own cost in China & will get rights to participate in Cytokinetics’ clinical trials. Cytokinetics will supply the product to Ji Xing
• The collaboration will use both companies' expertise to develop omecamtiv mecarbil for HF. Cytokinetics has also entered into CSPA for sale & issuance to RTW investors of 511,182 shares of Cytokinetics common stock

Ref: Globe Newswire | Image: Cytokinetics